Message Font: Serif | Sans-Serif
No. of Recommendations: 1

Boston Scientific (BSX ): Reiterates 4 STARS (accumulate)
Analyst: Robert Gold

Boston Scientific provided an update regarding the progress of the recent U.S. launch of its Taxus Express2 drug-coated coronary stent system. During the first two weeks of the launch, the company says it booked Taxus revenues of $42 million, with about 92,000 units shipped. Preliminary figures suggest that Taxus sales in the first quarter will likely exceed the high end of Boston Scientific's $52 million to $75 million target. Still, S&P is keeping the total U.S. cardiology first-quarter sales estimate at $400 million, and is retaining the earnings per share forecast at 27 cents. S&P believes the shares remain compelling as the Taxus story continues to unfold. S&P's 2004 earnings per share estimate remains $1.65.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.